Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P55774

UPID:
CCL18_HUMAN

ALTERNATIVE NAMES:
Alternative macrophage activation-associated CC chemokine 1; CC chemokine PARC; Dendritic cell chemokine 1; Macrophage inflammatory protein 4; Pulmonary and activation-regulated chemokine; Small-inducible cytokine A18

ALTERNATIVE UPACC:
P55774; B5BUM2; Q53X71

BACKGROUND:
The protein C-C motif chemokine 18, with aliases such as Macrophage inflammatory protein 4 and Small-inducible cytokine A18, is integral to the immune system's operation. It serves as a chemotactic factor for lymphocytes, not monocytes or granulocytes, and is crucial for B-cell migration into lymph node follicles. Its role in attracting naive T-cells, including CD4+ and CD8+ T-cells, to dendritic cells and macrophages in lymph nodes, underscores its importance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
The exploration of C-C motif chemokine 18's function offers promising avenues for therapeutic intervention. Its critical role in immune cell guidance underlines its potential as a therapeutic target, paving the way for the development of novel strategies in treating diseases with an immune component.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.